MedPage Today on MSN
CAR7 gene therapy shows promise in T-cell ALL
One patient still in remission 3 years after single infusion of base-edited CAR7 T cells ...
Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of ...
The FDA has granted breakthrough therapy designation (BTD) to soficabtagene geleucel (sofi-cel; WU-CART-007) for the ...
The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...
In a phase 1 study, anti-CD7 chimeric antigen receptor (CAR) T cells induced complete remission in children and adults with relapsed or refractory T-cell acute lymphoblastic leukemia (ALL), with 82% ...
Scientists at the University College London (UCL) have developed a novel therapy that helps treat patients with T cell acute lymphoblastic leukemia (T-ALL). This form of therapy used genome editing ...
CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.
A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond Street Hospital (GOSH), has shown promising results in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results